Drugs / Cobiprostone
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02542215 | Jun 2015 → Jul 2016 | mucositis | Sucampo Pharma Americas, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00737594 | Jul 2008 → Feb 2009 | portal hypertension | Sucampo Pharma Americas, LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00597818 | Aug 2007 → Apr 2009 | gastroduodenitis, osteoarthritis, rheumatoid arthritis | Sucampo Pharma Americas, LLC | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cobiprostone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00597818 ↗ |
| Known as | Cobiprostona | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103799 ↗ |
| Known as | RU-8811 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103799 ↗ |
| Known as | SPI-8811 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103799 ↗ |
| Action | Activate | “Chloride channel protein 2 activator” CHEMBL2103799 ↗ |
| Modality | Small molecule | — CHEMBL2103799 ↗ |
| Route | Oral | “18 mcg cobiprostone capsules for oral administration” NCT00597818 ↗ |
| Target | CLCN2 | “Chloride channel protein 2 activator” CHEMBL2103799 ↗ |